Abstract: Most experts consider that memantine has a symptomatic treatment, but clinical trials have not yet provided compelling evidence to support a disease-modifying effect. We investigate the effects of memantine on clinical ratings; fluorodeoxyglucose positron emission tomography (FDG-PET) measurements, which can monitor diseasemodifying effect; and cerebrospinal fluid (CSF) assays in patients with moderate to severe probable Alzheimer disease (AD) dementia. Twentytwo patients completed a 24-week, double-blind, placebo-controlled, randomized clinical trial of memantine, titrated up to 10 mg twice per day using the Severe Impairment Battery, AD Assessment Scale-Cognitive subscale, Mini-Mental State Examination, FDG-PET measurements of the regional cerebral metabolic rate for glucose (CMRgl), and CSF amyloid A (AA) and tau assays. An automated brain mapping algorithm and predefined regions of interest were each used to analyze treatmentrelated regional CMRgl effects. In comparison with the placebo group, the memantine treatment group had significantly less cognitive decline on the Severe Impairment Battery and significantly less CMRgl declines in regions preferentially affected by AD. There were no significant treatment effects on CSF AA 1-42 , CSF AA 1-40 , total tau, or phosphor-tau levels or ratios. This relatively small and brief randomized clinical trial suggests an association between memantine's clinical benefit and its effects on FDG-PET measurements in AD-affected brain regions. Larger and longer studies are needed to confirm these findings, extend them to earlier clinical and preclinical stages of AD, and help determine the extent to which FDG-PET should be qualified for use as a reasonably likely surrogate end point in the evaluation of putative ADmodifying treatments. M emantine is a low-to moderate-affinity uncompetitive N-methyl-D-aspartic acid (NMDA) receptor antagonist that has been approved for use in the treatment of moderate to severe Alzheimer disease (AD) dementia.
M
emantine is a low-to moderate-affinity uncompetitive N-methyl-D-aspartic acid (NMDA) receptor antagonist that has been approved for use in the treatment of moderate to severe Alzheimer disease (AD) dementia. 1, 2 To date, most experts consider the drug a symptomatic treatment, compensating for rather than slowing down or reversing the underlying disease, as clinical trials have not yet provided compelling evidence to support a disease-modifying effect. Still, several nonclinical studies have suggested that memantine may have beneficial effects on memory and learning by blocking sustained NMDA receptor activation by glutamate, reducing excitatory neurotoxicity, and increasing synaptic plasticity. Other nonclinical studies suggest that it might reduce production of the amyloid A (AA) peptide or reduce AA-mediated neurotoxicity. 3 If memantine's beneficial effects are related to increased synaptic activity, one could postulate that the drug increases synaptic activity in at least 3 possible (but not necessarily mutually exclusive) ways: (1) by increasing activity in neurons and brain regions that are relatively spared, compensating for preferentially affected neurons and synapses; (2) by increasing activity in neurons and brain regions that are preferentially affected by AD, either compensating for or mitigating diseased neurons and synapses; or (3) by attenuating the functional decline in neurons and brain regions that are preferentially affected by AD, modifying aspects of the disease itself.
In the last few years, there has been growing interest in the use of brain imaging and cerebrospinal fluid (CSF) biomarkers of AD to evaluate putative AD-modifying treatments in patients with AD dementia or mild cognitive impairment (MCI) and cognitively normal people at increased risk for AD. 4 To date, the best established biomarker end points include fluorodeoxyglucose positron emission tomography (FDG-PET) measurements of the cerebral metabolic rates for glucose (CMRgl) in brain regions preferentially affected by AD, volumetric magnetic resonance imaging (MRI) measurements of regional or whole-brain shrinkage, PET measurements of fibrillar AA deposition, and CSF AA 42 levels, alone or in combination with total tau (t-tau) or phospho-tau (p-tau) levels. Fluorodeoxyglucose PET measurements are thought to reflect the activity, density, and/or metabolism of terminal neuronal fields or perisynaptic glial cells 5 ; the MRI measurements are thought to reflect brain atrophy; the reduced CSF AA 42 levels are thought to reflect the deposition of this protein into diffuse or neuritic plaques, and elevated CSF t-tau and p-tau levels are thought to reflect some combination of neurofibrillary pathology or neurodegeneration, with release of these neuronal proteins into the interstitial space.
We recently proposed that the next step in the development of AD biomarkers and their possible qualification for use as primary end points in therapeutic and prevention trials is the use of different biomarkers in therapeutic trials of potential AD-modifying treatments. 6 This step is needed to help determine the extent to which an AD-modifying treatment moves these biomarkers, the extent to which it does so in the right direction (ie, without potentially confounding effects unrelated to disease-slowing), and the extent to which a treatment's biomarker effects are related to clinical outcome. Indeed, regulatory agencies are unlikely to qualify biomarker end points as primary end points in pivotal AD trials until there is evidence to show that an AD treatment's biomarker effects are reasonably likely to associate with a clinical benefit.
In a small 52-week randomized clinical trial (RCT) in patients with AD, memantine treatment was associated with nonsignificant trends suggesting reduced CMRgl declines in regional-to-pontine CMRgl decline in temporal, parietal, and other cerebral regions and reduced hippocampal shrinkage. 7 In a small 10-week open-label trial in patients with AD, memantine treatment was associated with increased CMRgl in temporal and parietotemporal regions bilaterally. 8 Although these FDG-PET findings need to be considered preliminarily, they are consistent with the possibility that memantine has neuroprotective or compensatory effects in neurons and brain regions that are preferentially affected by AD.
Here, we report a small 24-week RCT of memantine in patients with moderate to severe AD dementia using clinical ratings, FDG-PET, and CSF end points. We provide preliminary evidence to suggest that memantine treatment is associated with significantly less cognitive decline and significantly less CMRgl declines in regions preferentially affected by AD. There were no significant treatment effects on CSF AA , AA 1-40 , t-tau, or p-tau levels or ratios. Our findings support the possibility that an AD treatment's effects on FDG-PET measurements in AD-affected brain regions may be associated with its clinical benefit.
MATERIALS AND METHODS
The study was conducted between October 2008 and December 2010 at the Department of Geriatric Psychiatry, Shanghai Mental Health Center (SMHC), Shanghai Jiao Tong University School of Medicine. The SMHC institutional review board approved the consent form and study protocol, and the study was carried out in accordance with the Declaration of Helsinki. Patients enrolled in the hospital via self-referral or referral from family or physician. The study was approved by the institution's ethical committee, and informed consent was obtained from all subjects and/or their legal guardians.
Patients
Twenty-six patients with moderate to severe AD dementia participated in a 24-week double-blind, placebo-controlled RCT of memantine at the SMHC, including 22 patients who completed the trial. The ages of subjects we enrolled ranged from 50s to 90s. Before enrollment, patients' medical history was obtained, and physical and neurological examinations, laboratory tests, and T1-weighted and fluid-attenuated inversion recovery brain MRI were performed. Enrollment criteria included National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorder's Association criteria for probable AD 9 and Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition criteria for dementia of the Alzheimer's type; Mini-Mental State Examination (MMSE) scores between 4 and 20; a Hachinski Ischemia Score less than 4; systolic blood pressures between 95 and 160 mm Hg; diastolic blood pressures between 60 and 95 mm Hg; identification of a responsible and consistent caregiver; absence of diabetes, renal impairment, significant systemic conditions, psychiatric disorders, seizures, or traumatic brain injuries that could compromise their cognitive or brain functions or significant brain abnormalities on the patient's T1-weighted MRI; no more than 1 ischemic lacuna on the fluid-attenuated inversion recovery MRI; and absence of any approved or investigational antidementia drug in the previous 3 months.
Patients randomly assigned to the active or placebo treatment group received either memantine, titrated from the initial 5 mg/d to a dose of 10 mg twice daily over a 4-week period, or placebo and were treated for up to 24 weeks. Clinical ratings, neuropsychological tests, lumbar punctures, and FDG-PET scans were performed at baseline and 24-week follow-up visits.
Clinical Assessments
The Severe Impairment Battery (SIB) 10 was used to provide the trial's primary end point, as it has been shown to be more sensitive to the tracking of clinical decline in patients with moderate to severe AD dementia. Secondary end points included the MMSE, 11 the AD Assessment ScaleYCognitive (ADAS-Cog), 12 and the Neuropsychiatric Inventory, which assesses the presence and severity of neuropsychiatric symptoms and their impact on caregivers.
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Lumbar Punctures and CSF Assays
Lumbar punctures were performed, and 8 mL CSF was collected into glass tubes at the baseline and 24-week followup visits. Cerebrospinal fluid samples were kept in 0-C for a maximum of 1 hour, until centrifuged for 10 minutes at 3000g at 4-C, and transferred to and stored in polypropylene tubes as 2-mL aliquots at j80-C. Assays were performed in a single batch at the end of the study, blind to the treatment status.
Cerebrospinal fluid t-tau, p-tau 181 , AA40, and AA42 were determined using the commercially available enzyme-linked immunosorbent assay antigen kit from Invitrogen Corporation (Carlsbad, CA). For the t-tau assay, the minimum detectable level is 12 pg/mL, and the coefficients of variability (CVs) are 5.2% (intra-assay) and 7.8% (interassay). For the p-tau 181 , the minimum detectable level is 10 pg/mL, and CVs are 7.4% (intraassay) and 7.5% (interassay). For the AA 40 assay, the minimum detectable level is 6 pg/mL, and CVs are 2.5% (intra-assay) and 3.8% (interassay). For the AA 42 assay, the minimum detectable level is 10 pg/mL, and CVs are 3.5% (intra-assay) and 4.2% (interassay).
Fluorodeoxyglucose Positron Emission Tomography
Siemens Biograph 64-row PET/CT (Siemens, Berlin, Germany), a 30-minute emission scan, and a 5-minute postemission CT scan. Positron emission tomography images were reconstructed using filtered back projection, correction for radiation attenuation and scatter, and a 3.5-mm full-width-at-halfmaximum filter, resulting in one hundred forty-eight 3-mmthick horizontal sections and an in-plane resolution of 4.7 full width at half maximum.
Data Analysis
Demographic and clinical characteristics were compared in the active treatment and control groups using independentsample t tests for continuous measurements and W 2 test for data of categorical measurements.
An automated brain mapping algorithm (statistical parametric mapping version 8 [SPM8], www.fil.ion.ucl.ac.uk/spm/), the primary voxel-based analyses, supportive prespecified anatomical regions of interest (ROIs), and a post hoc exploratory prespecified statistical ROI (sROI) analysis were performed for FDG-PET images. Each patient's sequential images were aligned, spatially normalized to a standard Montreal Neurological Institute template, smoothed with an 8-mm Gaussian filter, and normalized for the individual variation in global PET counts using proportionate scaling. Statistical brain maps, generated using the general linear model, were used to characterize and compare between-visit changes in the active treatment and control groups on a voxel-by-voxel basis (our primary analysis). The statistical decline comparisons between the 2 groups were performed covarying out the baseline MMSE, SIB, and ADASCog because of the observed higher performance scores in the treatment group (although not statistically significant). As part of the primary voxel-based analysis, findings were corrected for the type I error associated with multiple regional comparisons using small volume correction (SVC) in bilateral precuneus/ posterior cingulate, parietal, temporal, and frontal ROIs thought to be preferentially affected by AD 14 using SPM8's Automated Anatomical Labeling (AAL) 15 toolbox and AAL ROIs precuneus/ posterior cingulate, parietal, temporal, and frontal, respectively. In line with the SVC procedure, we also performed analysis for data extracted from these AAL-ROIs to characterize and compare AD-related CMRgl in the active treatment and control groups. Using data from the AD Neuroimaging Initiative, we recently demonstrated the ability of an empirically predefined sROI to track AD-related CMRgl declines and evaluate ADmodifying treatments with improved statistical power 16 and free from the multiple comparisons. 17 Here, we also used this predefined sROI method to characterize and compare ADrelated CMRgl in the active treatment and control groups in a post hoc manner.
RESULTS
Two patients from the memantine treatment group and 2 patients from the placebo group did not complete the trial, leaving 11 completers in each group. The completer groups' demographic characteristics, baseline and 24-week clinical ratings, and between-visit clinical rating changes are shown in Table 1 . The memantine treatment and placebo groups did not differ significantly in their age, sex, or educational level. Although the groups did not differ significantly in their baseline clinical ratings, the memantine treatment group tended to have better performance on the MMSE (P = 0.10) and ADAS-Cog (P = 0.08) and, to a lesser extent, on the SIB (P = 0.17). We noted that the mean age was about 65 years. This was unusual for a convenience sample of AD patients. In the placebo control group, there were 5 cases in the 50-to 59-year age group, 3 cases in the 60-to 69-year age group, 1 case in the 70-to 79-year age group, and 2 cases in the 80-to 90-year age group. In the memantine group, there were 3 cases in the 50-to 59-year age group, 4 cases in the 60-to 69-year age group, 3 cases in the 70-to 79-year age group, and 1 case in the 80-to 90-year age group. Between these 2 groups, the age distribution was well balanced. More patients with dementia would have ischemic lacunas in their brain, which could impair their cognition at high age. This was an important reason that many patients older than 80 years were excluded in the research. We want to ensure that the patients who were recruited into our research were all pure AD patients.
Effects of Treatment on Clinical Ratings
In comparison with the placebo group, the memantine treatment group had significantly lower 24-week SIB score decline (P = 0.04), reflecting significantly less decline in the primary clinical end point (Table 1) . Noticing higher, though nonsignificantly, differences in baseline values, and the fact that change scores showed a significant difference only for SIB, we caution the clinical benefit of memantine over 24-weeks as modest.
Effects of Treatment on FDG-PET Measurements
Our primary voxel-based and ROI analyses revealed significantly less 24-week CMRgl declines in the memantine treatment group than in the placebo group, bilaterally, in brain regions known to be preferentially affected by AD. Both the memantine and placebo groups demonstrated 24-week CMRgl declines bilaterally in the vicinity of precuneus and posterior cingulate, lateral temporal and parietal, frontal, medial temporal, and occipital cortex (0.05 e P e 0.001, uncorrected, which remained significant in several of these regions using SVC). As illustrated by the cortical surface statistical map in Figure 1 , the memantine group had significantly smaller CMRgl declines bilaterally in precuneus/posterior cingulate, parietotemporal, and frontal cortex (0.05 e P e 0.003, uncorrected) and tended to be smaller in an AD-related sROI (P = 0.058).
Voxel-wise SPM analysis found that the placebo group had significant CMRgl decline in posterior cingulate (SVC, P = 0.01), left precuneus (SVC, P = 0.006), right precuneus (SVC, P = 0.008), left medial temporal (SVC, P = 0.004), left superior occipital (SVC, P = 0.05), left medial occipital (SVC, P = 0.017), and frontal (but uncorrected P = 0.005). In the treatment group, SPM analysis also found significant CMRgl declines in the right medial temporal (SVC, P = 0.001) and left superior occipital (SVC, P = 0.01) and other brain regions such as left and right precuneus and temporal cortical areas (uncorrected P = 0.005).
As seen in Figure 1 , voxel-based analysis showed that the CMRgl declines over the 24-week period in the memantine treatment group were significantly smaller than that in the placebo group in the posterior cingulate (SVC, P = 0.016) and left and right precuneus (SVC, P = 0.012 and P = 0.004, respectively). Smaller declines in the memantine group were also observed in the left and right temporal, medial temporal, frontal, and left/right occipital regions (P = 0.001 uncorrected). Greater CMRgl decline in the treatment group than that in the placebo group was also observed at right precentral and left insula (P = 0.005 uncorrected); none of them survived the SVC procedure. For the given uncorrected P = 0.005 type I threshold, we found that there were 1959 voxels where CMRgl declines in the memantine treatment group were significantly smaller than those in the placebo group, and there were only 178 voxels in the opposite direction. Monte-Carlo computer simulation with N = 1000 realizations was used to assess the probability that as many as 1959 survived P = 0.005 in 1 direction, and only as few as 178 survived the same threshold in the opposite direction. The Monte-Carlo simulation procedure estimated such probability is less than 0.001 (zero occurrence over the 1000 iterations).
Consistent with the results from the primary voxel-based analysis and as shown Figure 2 , our supportive ROI-based analysis demonstrated significantly smaller CMRgl declines in the memantine treatment group than in the placebo group in predefined posterior cingulate and left and right precuneus ROIs (2-tailed tests, P = 0.020, 0.026, and 0.003 respectively). There were also nonsignificant trends for smaller CMRgl declines in right occipital ROI in the treatment group (P = 0.094).
Finally, our post hoc sROI analysis showed CMRgl declines were observed in both the placebo group (mean, 0.042 [SD, 0.02]; P = 7.1ej05) and the memantine treatment group (0.019 [SD, 0.028]; P = 0.022). There was a nonsignificant trend for significantly (53%) less CMRgl decline in the memantine group than that in the placebo group (P = 0.058).
Effects of Treatment on CSF Biomarkers
The completer groups' baseline CSF AD biomarker (ie, AA42, AA40, t-tau, and p-tau 181 ) levels, 24-week CSF levels, and between-visit CSF level changes are shown in Table 2 . The memantine treatment and placebo groups did not differ significantly in any of these variables.
DISCUSSION
Starting our discussion, we acknowledge first some limitations: (1) the study is with small sample size and short treatment duration; (2) although statistically not significant (could be due to small sample size), baseline between-group cognitive measures/clinical ratings were not numerically balanced (higher MMSE numerically for memantine group at baseline); however, the findings of our FDG-PET analysis were independent of such difference; (3) we did not observe memantine-induced improvements for all cognitive measures. The change of our primary SIB before and after the treatment, however, was significant between the 2 groups (stable SIB in the memantine group and continued decline in the placebo group). Being aware of these limitations and discussing more details below, we note the significant attenuated decline of cerebral metabolic rate for glucose measured by FDG-PET in AD-affected brain regions in the memantine group as compared with the placebo group. Moreover, this positive FDG-PET finding was consistent with our primary SIB measurements.
This small 24-week, double-blind RCT used FDG-PET, CSF biomarkers, and clinical ratings to assess the effects of 24-week use of the competitive NMDA receptor antagonist memantine on local neuronal activity, AA and tau pathology, and clinical outcome in patients with moderate to severe AD dementia. Despite the small sample sizes and relatively short treatment duration, memantine treatment was associated with attenuated CMRgl decline in brain regions preferentially affected by AD. Our findings suggest that memantine's effects Memantine has been postulated to exert its therapeutic effects through its actions as a competitive NMDA receptor antagonist, reducing excitoxicity on preferentially affected neurons. 19 Other studies have reported but not confirmed memantine's ability to reduce the production of amyloid-A species that have been suggested to play a relatively early role in the pathogenesis of AD. Although our study failed to detect an effect on CSF measurements of AA or tau pathology, a negative finding could be attributed to the absence of a biological effect on these measurements, limited statistical power, or limited treatment duration. At present, there are no published postmortem data that can be used to assess the potential for memantine to either slow or reduce neuronal degeneration in patients with AD. Thus, whether long-term memantine treatment can reverse (ie, improve the function of sick but viable neurons) or prevent the damage to areas of the brain resulting from AD pathology remains unclear.
We and others have proposed the use of FDG-PET, volumetric MRI, and CSF measurements as end points in the evaluation of AD-modifying treatments based on data from longitudinal studies. 20 We have argued that biomarkers need to be embedded in clinical trials to determine the extent to which these AD biomarkers move in response to AD-modifying treatments, the extent to which they are associated with potentially confounding effects unrelated to disease slowing, 21 and the extent to which the treatment's biomarker effects associate with a clinical outcome. Indeed, regulatory agencies such as the Food and Drug Administration are unlikely to approve a treatment based solely on biomarker end points (ie, surrogate end points) without further evidence to suggest that a treatment's biomarker effects associate with a clinical benefit.
This study suggests the possible use of FDG-PET to detect the potential effects of certain AD treatments with unusually small sample sizes, and it supports the possibility that a treatment's effects on FDG-PET measurements in AD affected ROIsV and perhaps in an empirically predetermined sROIVcould associate with a clinical benefit. One might express surprise to see memantine's significant effects on CMRgl in AD-affected regions, because this drug is not widely considered to have strong disease-modifying effects, because the sample size was unusually small, and because the study duration was relatively short, and our sample size is indeed relatively younger. We suggest that we were able to detect this effect due in part to an increase in the activity of viable but affected neurons, whether or not it has longer-lasting disease-modifying effects. More generally, we postulate that AD-modifying treatments might have a relatively early effect on neuronal activity and that FDG-PET may for this very reason offer better sensitivity than structural brain measurements to detect a treatment effect. 22, 23 Elsewhere, we have discussed strategies to try to dissociate a treatment's effects on functional or structural brain imaging measurements unrelated to disease slowing, 20 an issue that merits further attention. Meantime, larger RCTs of memantine and other promising AD treatments and longer treatment durations are needed to confirm our findings and further support the role of FDG-PET as a reasonably likely surrogate end point in the evaluation of certain AD treatments. We also now acknowledge that the findings reported in our study with this small sample size and age distribution need to be examined further for their generalizability in older AD patients This small preliminary study suggests an association between memantine-related improvements in and/or slowing of cognitive decline in patients with moderate to severe AD dementia and an attenuated CMRgl decline in AD-affected brain regions. The data actually suggest that memantine improves function. Larger RCTs over longer treatment durations and using a range of biomarker end points and cytobiology researches are needed to confirm if memantine could really reduce disease progression, to relate the FDG-PET and other biomarker effects of different AD treatments to clinical outcome, and to clarify the extent to which these biomarkers could be used as reasonably likely surrogate end points in AD RCTs.
